Apellis Pharmaceuticals (APLS) Projected to Post Earnings on Friday

Apellis Pharmaceuticals (NASDAQ:APLS) will likely be announcing its earnings results before the market opens on Friday, February 28th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $197.92 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Apellis Pharmaceuticals Stock Performance

APLS opened at $26.99 on Wednesday. Apellis Pharmaceuticals has a 12-month low of $24.34 and a 12-month high of $71.90. The company has a market cap of $3.36 billion, a price-to-earnings ratio of -13.29 and a beta of 0.96. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company’s 50 day moving average is $30.34 and its 200 day moving average is $31.70.

Insider Buying and Selling

In related news, CEO Cedric Francois sold 2,824 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total transaction of $83,364.48. Following the sale, the chief executive officer now owns 415,695 shares of the company’s stock, valued at $12,271,316.40. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO James George Chopas sold 1,096 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the transaction, the chief accounting officer now owns 48,138 shares of the company’s stock, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,365 shares of company stock worth $1,810,479. Corporate insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $26.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, January 29th. Piper Sandler reduced their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Robert W. Baird cut their price objective on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Finally, Morgan Stanley assumed coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price on the stock. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).